NewAmsterdam Pharma Presents Obicetrapib CETP Inhibitor Alzheimer's-Prevention Data at AAIC 2026 Wednesday July 15 Poster Session (7:30 AM-4:30 PM BST, ICC Maritime Hall): The BROADWAY Phase 3 Cardiovascular Trial Showed Statistically Significant Absolute Reductions in Plasma P-Tau217 Versus Placebo Over 12 Months in the Full Analysis Set (n=1,535, p=0.025) and in ApoE4 Carriers (n=367, p=0.022), Alongside Favorable Trends in Other Alzheimer's Disease Biomarkers — First Randomized Biomarker Signal for a CETP Inhibitor in Alzheimer's Prevention
NewAmsterdam Pharma (NASDAQ: NAMS) presented obicetrapib CETP inhibitor Alzheimer's-prevention biomarker data at AAIC 2026 in London on Wednesday July 15, 2026 in a poster session (7:30 AM-4:30 PM BST at ICC Maritime Hall) titled 'CETP Inhibition for Alzheimer's Prevention: Obicetrapib's Multi-Pathway Effects on Lipid Mediated Pathophysiology' (Abstract 2026-A-5685-AAIC, Poster 0056). The Phase 3 BROADWAY cardiovascular-outcomes trial (obicetrapib as an oral, low-dose, once-daily CETP inhibitor adjunct to statin therapy) documented statistically significant reductions in absolute plasma p-tau217 versus placebo over 12 months. Full analysis set: n=1,535, p=0.025. In ApoE4 carriers (the highest-risk Alzheimer's-genetic subgroup): n=367, p=0.022. NewAmsterdam also reported favorable trends in other AD biomarkers. Obicetrapib's mechanism is CETP inhibition to raise HDL cholesterol and lower LDL, but the AD-biomarker signal supports a dual cardiovascular-plus-Alzheimer's-prevention thesis. Obicetrapib was well-tolerated in BROADWAY with safety comparable to placebo. NewAmsterdam is advancing obicetrapib toward regulatory filings on the LDL-C indication and is in EMA review with dual cardiovascular and neurology positioning.